Shots:

• The US FDA has granted Breakthrough Therapy Designation to adagrasib in combination with cetuximab for KRASG12C- mutated, advanced CRC whose cancer has progressed following prior treatment with CT & anti-VEGF therapy
• The designation was based on the P-Ib cohort of the P-Ib/II (KRYSTAL-1) trial evaluating adagrasib as monotx. or combined with cetuximab. The combination therapy showed ORR (46%); m-DoR of 7.6mos. and an m-PFS of 6.9mos. The safety profile was consistent with prior reported results, grade 3 or 4 TRAEs (34%) who received adagrasib monotx. & 16% in combination with no grade 5 TRAEs
• The combination therapy is being studied in an ongoing P-III trial for KRASG12C-mutated CRC. Adagrasib also received the BTD from the US FDA for NSCLC harboring KRASG12C- mutation 

Ref: prnewswire | Image: Mirati 

Related Posts:- Mirati Therapeutics’ Krazati (adagrasib) Receives the US FDA’s Approval as a Targeted Treatment Option for Non-Small Cell Lung Cancer with a KRASG12C Mutation